Literature DB >> 2183082

Intracerebral NGF infusion induces hyperinnervation of cerebral blood vessels.

L G Isaacson1, B N Saffran, K A Crutcher.   

Abstract

The use of intracerebral NGF (nerve growth factor) infusions as a therapeutic tool to prevent the degeneration of cholinergic neurons in humans suffering from Alzheimer's disease has recently been suggested. In the present study, intracerebroventricular infusion of nerve growth factor into the adult rat brain was found to induce axonal sprouting of mature, uninjured axons associated with the intradural segment of the internal carotid artery. Following NGF infusion, a three-fold increase in the total number of axons associated with the vessel wall was observed when compared with vehicle-infused animals. This vascular hyperinnervation might also occur in humans. Before NGF infusion therapy is initiated, more research is necessary concerning the specificity, mechanisms, and functional significance of the sprouting response observed in this study.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2183082     DOI: 10.1016/0197-4580(90)90062-5

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  14 in total

Review 1.  Gene therapy in clinical medicine.

Authors:  S M Selkirk
Journal:  Postgrad Med J       Date:  2004-10       Impact factor: 2.401

Review 2.  Potential therapeutic uses of BDNF in neurological and psychiatric disorders.

Authors:  Alan H Nagahara; Mark H Tuszynski
Journal:  Nat Rev Drug Discov       Date:  2011-03       Impact factor: 84.694

3.  Comparison of Linear and Cyclic His-Ala-Val Peptides in Modulating the Blood-Brain Barrier Permeability: Impact on Delivery of Molecules to the Brain.

Authors:  Ahmed Alaofi; Ngoc On; Paul Kiptoo; Todd D Williams; Donald W Miller; Teruna J Siahaan
Journal:  J Pharm Sci       Date:  2016-02       Impact factor: 3.534

4.  Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy.

Authors:  D E Smith; J Roberts; F H Gage; M H Tuszynski
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

5.  Plasticity in expression of calcitonin gene-related peptide and substance P immunoreactivity in ganglia and fibres following guanethidine and/or capsaicin denervation.

Authors:  M C Mione; J F Cavanagh; K A Kirkpatrick; G Burnstock
Journal:  Cell Tissue Res       Date:  1992-06       Impact factor: 5.249

6.  Behavioural and neurochemical effects of superior cervical ganglionectomy in rats with septo-hippocampal lesions.

Authors:  A M Bratt; J C Cassel; B Neufang; P L Greene; R Jackisch; G Hertting; B E Will
Journal:  Exp Brain Res       Date:  1995       Impact factor: 1.972

7.  Characterization of trkB immunoreactive cells in the intermediolateral cell column of the rat spinal cord.

Authors:  Annemarie M McCartney; Vanessa L Abejuela; Lori G Isaacson
Journal:  Neurosci Lett       Date:  2008-05-21       Impact factor: 3.046

8.  Functional multipotency of stem cells: a conceptual review of neurotrophic factor-based evidence and its role in translational research.

Authors:  Yang D Teng; Dou Yu; Alexander E Ropper; Jianxue Li; Serdar Kabatas; Dustin R Wakeman; Junmei Wang; Maryrose P Sullivan; D Eugene Redmond; Robert Langer; Evan Y Snyder; Richard L Sidman
Journal:  Curr Neuropharmacol       Date:  2011-12       Impact factor: 7.363

9.  Current advances in using neurotrophic factors to treat neurodegenerative disorders.

Authors:  April M Weissmiller; Chengbiao Wu
Journal:  Transl Neurodegener       Date:  2012-07-26       Impact factor: 8.014

10.  From molecular to nanotechnology strategies for delivery of neurotrophins: emphasis on brain-derived neurotrophic factor (BDNF).

Authors:  Claire Géral; Angelina Angelova; Sylviane Lesieur
Journal:  Pharmaceutics       Date:  2013-02-08       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.